Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma

Interventions

DRUG

Fulvestrant

Given by PO

DRUG

Repotrectinib

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER